Boston Scientific WallFlex™ Esophageal Stent Gains CE Mark For The Treatment Of Refractory Benign Esophageal Strictures

Boston Scientific WallFlex™ EsophagealBoston Scientific WallFlex™ Esophageal Stent Gains CE Mark For The Treatment Of Refractory Benign Esophageal Strictures PR Newswire NATICK, Massachusetts, Feb. 14, 2014 - Fully Covered Metal Stent Provides New Treatment Option for Patients with Refractory Benign Esophageal Strictures Boston Scientific Corporation (NYSE: BSX) has received CE Mark in Europe for its WallFlex™ Esophageal Fully Covered Stent to treat refractory benign esophageal strictures. Benign esophageal strictures are a narrowing of the esophagus caused by scar tissue.[i] The primary treatment is dilation of the esophagus, which may need to be repeated after a period of time if the stricture recurs.[ii] "Fully covered esophageal stents are a valid therapeutic option in patients with benign refractory esophageal strictures," said Dr. Javier Jimenez, chief of the Endoscopy Department at Complejo Hospitalario de Navarra in Pamplona, Spain. "I use the WallFlex Esophageal Stent because its small profile and radiopacity facilitate accurate placement, the migration rate is low and stent removal is usually easy." "The advantage of the WallFlex Esophageal Fully Covered Stent is its ease of use and now removability, which allows me to treat patients with refractory benign strictures," said Peter D. Siersema, M.D., Ph.D., professor of Gastroenterology and head of the Department of Gastroenterology and Hepatology at University Medical Center in Utrecht, The Netherlands.